GSK Korea's Establishment of Vaccine Production Facility Still Under Discussion

Published: 2005-01-19 06:56:00

Updated: 2005-01-19 06:56:00

In reaction to a number of reports recently made by the domestic daily newspapers that GlaxoSmithKline (GSK) Korea would establish a large-scale vaccine production facility in the Gyeonggi province, the company stated that no such decision has yet been approved by the GSK corporate headquarter.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK